Drug Response Metrics in Cancer In Vitro
2026-09-17
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how in vitro cancer drug responses combine proliferative arrest and cell death. Its central finding is that most drugs influence both processes, but with different magnitudes and timing, supporting time-resolved, endpoint-specific interpretation rather than reliance on a single viability value.
PSI-7977: A Mechanistic Guide to Safer Assays
2026-09-17
PSI-7977 can strengthen mechanism-aware experimental design when it is treated as a defined antiviral comparator rather than an assumed disulfidptosis reagent. This guide connects PSI-7977 assay positioning with BAP1, SLC7A11, cystine, and NADPH biology while highlighting essential controls and interpretation limits.
PNU 74654: Wnt Signaling Workflow Guide
2026-09-16
Build reproducible Wnt/β-catenin perturbation assays with PNU 74654, from DMSO stock preparation to orthogonal pathway validation. The workflow connects cancer research, stem cell research, and muscle progenitor biology while clearly separating evidence-backed findings from practical assay recommendations.
HyperScribe T7 High Yield RNA Synthesis Kit
2026-09-15
The HyperScribe T7 High Yield RNA Synthesis Kit is an in vitro transcription RNA kit for high-yield T7 RNA polymerase transcription. The K1047 format supports research workflows involving modified, capped, dye-labeled, or biotinylated RNA, with a reported yield of up to approximately 50 μg per 20 μL reaction.
GLP-1 (9-36) Amide: A Causal Assay Framework
2026-09-15
GLP-1 (9-36) amide can do more than block a receptor: it can help researchers distinguish GLP-1 receptor-dependent signaling from ligand crosstalk and assay artifacts. This guide translates high-throughput cAMP findings into a rigorous workflow for GLP-1 receptor signaling research and metabolic studies.
SMYD2–miR-125b Signaling in RCC Drug Resistance
2026-09-14
The reference study identifies SMYD2 as an adverse prognostic factor and mechanistic driver of clear cell renal cell carcinoma through regulation of the miR-125b/DKK3 axis. Its integrated clinical, molecular, cellular, and xenograft evidence also connects SMYD2 inhibition with reduced P-glycoprotein activity and improved sensitivity to several anticancer drugs, including fluorouracil.
RITA (NSC 652287): Reliable Assay Design
2026-09-14
Learn how RITA (NSC 652287), SKU A4202, can support better-designed viability, proliferation, and cytotoxicity studies. This scenario-based guide connects its nanomolar activity and formulation requirements with practical assay controls, readout interpretation, and vendor-selection criteria.
nor-NOHA Workflows for Arginase and AML Research
2026-09-13
Build mechanism-aware assays around reversible arginase inhibition, from HepG2 apoptosis and invasion studies to AML immunometabolism. This guide connects nor-NOHA acetate with CD36-driven immune escape while separating evidence-backed findings from practical assay recommendations.
Glutathione Redox Signals in Hypoxic Tumors
2026-09-12
Hypoxia and immunometabolic competition reshape the tumor microenvironment, but mechanistic models need quantitative redox evidence. This thought-leadership article explains how paired GSH and GSSG measurements can strengthen studies of hypoxic tumors, immune dysfunction, and translational biomarker development. It connects the findings of a recent Cancer Letters review with practical assay strategy and positions the GSH and GSSG Assay Kit as a focused tool for reduced glutathione detection, oxidized glutathione measurement, and redox state analysis across relevant biological matrices.
Cyclopamine: Hedgehog Signaling Workflows
2026-09-12
Cyclopamine is a practical Smoothened-directed tool for separating Hedgehog pathway effects from downstream cell and tissue phenotypes. This guide connects cancer-cell assays with comparative genital-tubercle development studies, emphasizing dosing, controls, readouts, and troubleshooting.
Fluorouracil Assay Design for Solid Tumor Models
2026-09-11
Build reproducible 5-Fluorouracil workflows around thymidylate synthase inhibition, DNA-replication stress, and orthogonal cell-death readouts. This guide also shows how to use Fluorouracil as a cytotoxic benchmark when evaluating Wnt/β-catenin–directed strategies in colon cancer research, while keeping combination claims experimentally grounded.
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-09-11
Build a reproducible HRP-based workflow for protein-level evidence in radiation and ferroptosis studies. This practical guide connects ECL detection with DHODH, ACSL4, and GPX4 analysis while emphasizing exposure control, assay boundaries, and troubleshooting.
Bestatin and Actinonin: Intracellular Action
2026-09-10
The reference study used matched antiproliferative and aminopeptidase assays, together with drug-efflux modifiers, to show that bestatin and actinonin act predominantly through intracellular mechanisms rather than cell-surface aminopeptidase inhibition alone. Its transporter-focused design provides a useful framework for interpreting inhibitor accumulation, apparent resistance, and pharmacological interactions in hematologic cancer models.
2-Deoxy-D-glucose and Lactylation-Aware Assays
2026-09-10
2-Deoxy-D-glucose is more than a glycolysis inhibitor: it can help position metabolic stress within lactate-linked epigenetic pathways. This article connects 2-DG assay design with the H3K18 lactylation–METTL5–CCT2 axis while defining practical boundaries for cancer and antiviral research.
CD36-Driven Immune Escape in AML
2026-09-09
A 2024 Cell Reports Medicine study identifies a non-canonical CD36 program in which oxidized LDL and palmitate activate innate immune signaling in AML cells and suppress antitumor T-cell responses. The work connects lipid availability and decitabine resistance, while showing that statin-mediated lipid restriction can improve decitabine efficacy in preclinical models.